Papers - FUJITA Naoki
-
Relationships of low-grade systemic inflammation and nutritional status with erectile dysfunction severity in men on dialysis
Naoki Fujita, Shingo Hatakeyama, Masaki Momota, Tomoko Hamaya, Yuki Tobisawa, Tohru Yoneyama, Teppei Okamoto, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Kazuaki Yoshikawa, Chikara Ohyama
Andrology 2022.11
-
Humoral response after SARS-CoV-2 mRNA vaccination in patients with prostate cancer using steroids
Noritaka Ishii, Shingo Hatakeyama, Tohru Yoneyama, Ryuma Tanaka, Takuma Narita, Naoki Fujita, Teppei Okamoto, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama
Urologic Oncology 2022.10
-
Risk score-based substratification improves surveillance costs after transurethral resection of bladder tumor in patients with primary high-risk non-muscle-invasive bladder cancer
Naoki Fujita, Shingo Hatakeyama, Masaki Momota, Yuki Tobisawa, Tohru Yoneyama, Hayato Yamamoto, Hiroyuki Ito, Takahiro Yoneyama, Yasuhiro Hashimoto, Kazuaki Yoshikawa, Chikara Ohyama
Scientific Reports 2022.8
-
Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guérin therapy
Naoki Fujita, Shingo Hatakeyama, Masaki Momota, Takuma Narita, Yuki Tobisawa, Tohru Yoneyama, Hayato Yamamoto, Hiroyuki Ito, Takahiro Yoneyama, Yasuhiro Hashimoto, Kazuaki Yoshikawa, Chikara Ohyama
International Journal of Urology 2022.8
-
Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapy
Hiromichi Iwamura, Shingo Hatakeyama, Takuma Narita, Yusuke Ozaki, Sakae Konishi, Hirotaka Horiguchi, Hirotake Kodama, Yuta Kojima, Naoki Fujita, Teppei Okamoto, Yuki Tobisawa, Tohru Yoneyama, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama
Scientific Reports 2022.6
-
Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma
Kyo Togashi, Shingo Hatakeyama, Tohru Yoneyama, Tomoko Hamaya, Takuma Narita, Naoki Fujita, Hiromichi Iwamura, Teppei Okamoto, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama
International journal of urology 2022.6
-
Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients
Tomoko Hamaya, Shingo Hatakeyama, Tohru Yoneyama, Yuki Tobisawa, Hirotake Kodama, Takeshi Fujita, Reiichi Murakami, Naoki Fujita, Teppei Okamoto, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Hisao Saitoh, Shunji Narumi, Hirofumi Tomita, Chikara Ohyama
Scientific Reports 2022.4
-
Associations of impaired grip strength and gait function with the severity of erectile dysfunction in men undergoing dialysis: a cross-sectional study
Naoki Fujita, Shingo Hatakeyama, Masaki Momota, Yuki Tobisawa, Tohru Yoneyama, Teppei Okamoto, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Kazuaki Yoshikawa, Chikara Ohyama
The Aging Male 2021.12
-
Management of bladder cancer in older patients
Shingo Hatakeyama, Shintaro Narita, Kazutaka Okita, Takuma Narita, Hiromichi Iwamura, Naoki Fujita, Junichi Inokuchi, Yoshiyuki Matsui, Hiroshi Kitamura, Chikara Ohyama
Japanese journal of clinical oncology 2021.12
-
The cell surface hyaluronidase TMEM2 is essential for systemic hyaluronan catabolism and turnover
Yuki Tobisawa, Naoki Fujita, Hayato Yamamoto, Chikara Ohyama, Fumitoshi Irie, Yu Yamaguchi
The Journal of biological chemistry 2021.11
-
Oncologic and patient-reported outcomes after robot-assisted radical prostatectomy in men aged ≥75 years
Kyo Togashi, Shingo Hatakeyama, Teppei Okamoto, Yuta Kojima, Hiromichi Iwamura, Naoki Fujita, Takuma Narita, Itsuto Hamano, Tomoko Hamaya, Tohru Yoneyama, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama
Urologic oncology 2021.10
-
The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma
Kai Ozaki, Shingo Hatakeyama, Toshikazu Tanaka, Daisuke Noro, Noriko Tokui, Hirotaka Horiguchi, Yoshiharu Okuyama, Naoki Fujita, Teppei Okamoto, Akiko Okamoto, Yuichiro Suzuki, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama
BJUI Compass 2021.8
-
Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer
Yuki Miura, Shingo Hatakeyama, Toshikazu Tanaka, Naoki Fujita, Hirotaka Horiguchi, Yoshiharu Okuyama, Yuta Kojima, Daisuke Noro, Noriko Tokui, Teppei Okamoto, Hayato Yamamoto, Hiroyuki Ito, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama
BJUI Compass 2021.8
-
The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma
Okita K, Hatakeyama S, Hagiwara K, Suzuki Y, Tanaka T, Noro D, Tokui N, Fujita N, Konishi S, Okamoto T, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C
2021.4
-
Prognostic significance of the Ki67 index and programmed death-ligand 1 expression after radical cystectomy in patients with muscle-invasive bladder cancer
Horiguchi H, Hatakeyama S, Yoneyama T, Yoneyama MS, Tanaka T, Fujita N, Okamoto T, Yamamoto H, Yoneyama T, Yoshizawa T, Hashimoto Y, Kawaguchi T, Ohyama C
39 ( 4 ) 238.e9 - 238.e17 2021.4
-
Effect of frailty and comorbidity on surgical contraindication in patients with localized prostate cancer (FRART-PC Study)
Kodama H, Hatakeyama S, Momota M, Togashi K, Hamaya T, Hamano I, Fujita N, Kojima Y, Okamoto T, Yoneyama T, Yamamoto H, Yoshikawa K, Yoneyama T, Hashimoto Y, Ohyama C
39 ( 3 ) 191.e1 - 191.e8 2021.3
-
Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy
Fujita N, Hatakeyama S, Okita K, Momota M, Narita T, Tobisawa Y, Yoneyama T, Yamamoto H, Imai A, Ito H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C
39 ( 3 ) 191.e9 - 191.e16 2021.3
-
Impact of symptomatic recurrence on oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer
Fujita N, Hatakeyama S, Momota M, Tobisawa Y, Yoneyama T, Yamamoto H, Imai A, Ito H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C
39 ( 3 ) 194.e9 - 194.e16 2021.3
-
Relationship of frailty with treatment modality selection in patients with muscle-invasive bladder cancer (FRART-BC study)
Iwamura H, Hatakeyama S, Momota M, Kojima Y, Narita T, Okamoto T, Fujita N, Hamano I, Togashi K, Hamaya T, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C
Translational andrology and urology 10 ( 3 ) 1143 - 1151 2021.3
-
The effect of frailty on the quality of life and lower urinary symptoms following robot-assisted radical prostatectomy: A longitudinal analysis (FRARP-QL Study)
Togashi K, Hatakeyama S, Kojima Y, Momota M, Narita T, Iwamura H, Hamano I, Hamaya T, Fujita N, Okamoto T, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C
39 ( 3 ) 192.e7 - 192.e14 2021.3